Wendy Xiong
Buchang Pharma (China)(CN)
Publications by Year
Research Areas
Diabetes Treatment and Management, Pancreatic function and diabetes, Drug Transport and Resistance Mechanisms, Pediatric Hepatobiliary Diseases and Treatments, Bone health and osteoporosis research
Most-Cited Works
- → Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes(2017)64 cited
- → Effect of LX4211 on Glucose Homeostasis and Body Composition in Preclinical Models(2014)51 cited
- → LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice(2017)34 cited
- → Effects of bile acids on expression of the human apical sodium dependent bile acid transporter gene(2007)18 cited
- → LP‐925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2(2015)13 cited
- → Transactivation of the human apical sodium-dependent bile acid transporter gene by human serum(2007)10 cited
- → MicroCT analyses of mouse femoral neck architecture(2019)8 cited
- → Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer)(2018)5 cited
- → A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies(2021)3 cited
- → A phase I, first-in-human, dose-escalation and dose-expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.(2019)1 cited